UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 11, 2016 (February 8, 2016)

 

VIROPRO, INC.

(Exact Name of Registrant as Specified in Charter)

 

Nevada   333-06718   13-3124057
(State or Other Jurisdiction   (Commission File Number)    (IRS Employer
of Incorporation)        Identification No.)

 

2151 O'Toole Avenue, Suite 50, San Jose, CA 95131

 (Address of Principal Executive Offices) (Zip Code)

 

650-300-5190

Registrant’s telephone number, including area code

 

        N/A         

 (Former Name or Former Address

if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
   

 

 

 
 

  

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On February 8, 2016, the registrant ("Viropro") appointed John Doll to a vacancy on the Viropro Board of Directors. Mr. Doll retired in October 2009 as Acting Under Secretary of Commerce for Intellectual Property and Acting Director of the United States Patent and Trademark Office (the "USPTO"). He began his career at the USPTO in 1974 as an assistant examiner, became Supervisory Patent Examiner, having examined and supervised the examination of patent applications encompassing pharmaceuticals, herbicides, pesticides, dyestuffs, inorganic chemistry, hydrometallurgy, zeolite catalysts, buckministerfullerenes, proteins, and peptides, and became Director of Patent Examination responsible for all patent examination issues in the chemistry, chemical engineering, pharmaceutical, biotechnology and design art areas. Before that he was Supervisory Patent Examiner, having examined and supervised the examination of patent applications encompassing pharmaceuticals, herbicides, pesticides, dyestuffs, inorganic chemistry, hydrometallurgy, zeolite catalysts, buckministerfullerenes, proteins, and peptides. During his time at the USPTO, Mr. Doll received numerous awards for the implementation of the Patent Application Location and Monitoring (PALM) system, the development and implementation of the automated examiner Office Action tools, for establishing the Biotechnology Customer Partnership, and for the implementation of the Image File Wrapper system. The terms of compensation for Mr. Doll are still being negotiated by the Board with Mr. Doll.

 

Viropro issued a press release on February 11, 2016 to disclose these events, a copy of which is attached to this Current Report on Form 8-K as Exhibit 99.1.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

  99.1  Press Release dated February 11, 2016

 

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

Date: February 11, 2016 Viropro, Inc.  
       
  By: /s/ Kenneth A. Sorensen  
    Kenneth A. Sorensen  
    Chairman of the Board  

       

 

 

 

 

 

 

Exhibit 99.1

 

 

 

PHARMACEUTICAL AND BIOTECHNOLOGY PATENT EXPERT JOHN DOLL JOINS VIROPRO BOARD

 

Doll was former Acting Under Secretary of Commerce for Intellectual Property and Acting Commissioner of the United States Patent and Trademark Office

 

FEBRUARY 11, 2016, SAN JOSE, CA. – Viropro, Inc. (OTCBB: VPRO), which has previously announced it will be changing its name to Axxiom, today announced that John Doll has agreed to join its Board of Directors effective immediately.

 

John Doll retired in October 2009 as Acting Under Secretary of Commerce for Intellectual Property and Acting Director of the United States Patent and Trademark Office (USPTO), where he was responsible for advising the President, the Secretary of Commerce and the Administration about all intellectual property matters. John began his career at USPTO in 1974 as an assistant examiner, and progressed to be Director of Patent Examination responsible for all patent examination issues in the chemistry, chemical engineering, pharmaceutical, biotechnology and design art areas. Before that he was Supervisory Patent Examiner, having examined and supervised the examination of patent applications encompassing pharmaceuticals, herbicides, pesticides, dyestuffs, inorganic chemistry, hydrometallurgy, zeolite catalysts, buckministerfullerenes, proteins, and peptides. “We are delighted and honored to have someone of John’s stature, as a former commissioner of the United States Patent Office, join our Board,” said Dr. Ken Sorensen, Viropro Chairman of the Board. “His decades of experience as a career patent official who rose through the ranks to become the Head of the Office, and his leadership during some of the most formidable changes in the landscape of US and international patent law, will be invaluable to help guide the transformation of Viropro as we continue our efforts to build a world-class company.”

 

During his time at the USPTO, John won numerous awards for the implementation of the Patent Application Location and Monitoring (PALM) system, the development and implementation of the automated examiner Office Action tools, for establishing the Biotechnology Customer Partnership, and for the implementation of the Image File Wrapper system. “I am excited to join the Board of Viropro as we create a diversified life sciences company focusing on the development of high value therapeutic drugs and services,” Doll said.

 

 
 

 

This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the company’s limited cash reserves and its ability to obtain additional capital on acceptable terms, or at all, including the additional capital which will be necessary to execute the company’s future plans.

 

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The company has no obligation, and expressly disclaims any obligation to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

 

For more information, visit www.viropro.net / CONTACT: Viropro Public Relations (info@viropro.net).